Oral hypoglycaemic agent failure

Related Experiment Video

Updated: Sep 26, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

S Banerjee1, K Sinharoy, A K Singh

  • 1Department of Medicine, NRS Medical College, Kolkata 700014.

Journal of the Indian Medical Association
|April 4, 2003
PubMed

Insights

Type 2 diabetes patients may develop resistance to oral hypoglycaemic agents (OHA), leading to insulin dependence. Early detection of OHA failure, caused by poor diet compliance and beta-cell function decline, is crucial for managing diabetes.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes management often involves diet, exercise, and oral hypoglycaemic agents (OHA).
  • A significant portion of patients develop primary or secondary resistance to OHA, necessitating insulin therapy.
  • Poor adherence to dietary recommendations and declining beta-cell function are primary drivers of OHA failure.

Purpose of the Study:

  • To highlight the importance of early detection of oral hypoglycaemic agent failure in type 2 diabetes.
  • To emphasize the need for timely intervention to prevent disease progression and complications.
  • To underscore the role of comprehensive patient assessment in optimizing diabetes management.

Main Methods:

  • This study is a review of existing literature on OHA failure in type 2 diabetes.
  • It analyzes the causes and incidence rates of primary and secondary OHA failure.
  • The focus is on the clinical implications and management strategies for OHA failure.

Main Results:

  • The annual incidence of OHA failure ranges from 3% to 30%.
  • Primary and secondary OHA failure are significant challenges in achieving long-term glycemic control.
  • Deterioration of beta-cell function and poor diet compliance are identified as key contributing factors.

Conclusions:

  • Early recognition and assessment of OHA failure are critical for effective diabetes management.
  • Prompt therapeutic adjustments can help preserve beta-cell function and potentially delay insulin requirement.
  • Comprehensive management strategies are essential for patients to lead normal lives despite diabetes.

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...